Cargando…

Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) have revolutionized treatment of advanced melanoma and survival of melanoma patients has radically improved since. However, as durable responses after ICIs are only observed in 30–50% of melanoma patients, there is an unmet need to identify predict...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baltussen, Joosje C., Welters, Marij J. P., Verdegaal, Elizabeth M. E., Kapiteijn, Ellen, Schrader, Anne M. R., Slingerland, Marije, Liefers, Gerrit-Jan, van der Burg, Sjoerd H., Portielje, Johanneke E. A., de Glas, Nienke A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699321/ https://www.ncbi.nlm.nih.gov/pubmed/34944986 http://dx.doi.org/10.3390/cancers13246366

Ejemplares similares

Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer
por: van Holstein, Yara, et al.
Publicado: (2019)

Improved survival of older patients with advanced breast cancer due to an increase in systemic treatments: a population-based study
por: de Glas, Nienke, et al.
Publicado: (2019)

Chemotherapy-Related Toxic Effects and Quality of Life and Physical Functioning in Older Patients
por: Baltussen, Joosje C., et al.
Publicado: (2023)

Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study
por: Verdegaal, Els, et al.
Publicado: (2020)

Time Trends in Treatment Strategies and Survival of Older versus Younger Patients with Synchronous Metastasised Melanoma—A Population-Based Study in the Netherlands Cancer Registry
por: van der Ziel, Daisy, et al.
Publicado: (2022)

Patient Preferences for Treatment Outcomes in Oncology with a Focus on the Older Patient—A Systematic Review
por: Seghers, Petronella A. L. (Nelleke), et al.
Publicado: (2022)

Detection and functional assessment of regulatory T cells in clinical samples
por: Santegoets, Saskia, et al.
Publicado: (2014)

Prediction of Other-Cause Mortality in Older Patients with Breast Cancer Using Comorbidity
por: de Boer, Anna Z., et al.
Publicado: (2021)

Effectiveness of radiotherapy after breast-conserving surgery in older patients with T1-2N0 breast cancer
por: de Boer, Anna Z., et al.
Publicado: (2019)

Design and rationale of a routine clinical care pathway and prospective cohort study in older patients needing intensive treatment
por: van Holstein, Yara, et al.
Publicado: (2021)

The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma
por: Welters, Marij J. P., et al.
Publicado: (2020)

Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
por: Tong, Justin, et al.
Publicado: (2022)

Beyond Platinum, ICIs in Metastatic Cervical Cancer: A Systematic Review
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial
por: van der Kooij, Monique K, et al.
Publicado: (2020)

Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency
por: Xiang, Jing, et al.
Publicado: (2023)

Monitoring of the Immune Dysfunction in Cancer Patients
por: Santegoets, Saskia J. A. M., et al.
Publicado: (2016)

The combined HPV16-E2/E6/E7 T cell response in oropharyngeal cancer predicts superior survival
por: Santegoets, Saskia J., et al.
Publicado: (2023)

Early stage breast cancer treatment and outcome of older patients treated in an oncogeriatric care and a standard care setting: an international comparison
por: de Boer, Anna Z., et al.
Publicado: (2020)

Role of patient preferences in clinical practice guidelines: a multiple methods study using guidelines from oncology as a case
por: Gärtner, Fania R, et al.
Publicado: (2019)

Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer
por: Hurkmans, Daan P, et al.
Publicado: (2020)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
por: Naimi, Adel, et al.
Publicado: (2022)

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors †
por: de Glas, Nienke A., et al.
Publicado: (2021)

Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI) Versus Non-ICI Era: A Population-Based Study
por: Safi, Mohammed, et al.
Publicado: (2021)

Effect of implementation of the mass breast cancer screening programme in older women in the Netherlands: population based study
por: de Glas, Nienke A, et al.
Publicado: (2014)

The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy
por: Verdegaal, Els M. E., et al.
Publicado: (2017)

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
por: Vafaei, Somayeh, et al.
Publicado: (2022)

Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types
por: van der Kooij, Monique K., et al.
Publicado: (2019)

Human Papillary and Reticular Fibroblasts Show Distinct Functions on Tumor Behavior in 3D-Organotypic Cultures Mimicking Melanoma and HNSCC
por: Wu, Shidi, et al.
Publicado: (2022)

Physical Function and Physical Activity in Older Breast Cancer Survivors: 5-Year Follow-Up from the Climb Every Mountain Study
por: Lemij, Annelieke A, et al.
Publicado: (2023)

Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years
por: Paaso, Anna, et al.
Publicado: (2015)

Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors
por: Zhang, Xin, et al.
Publicado: (2022)

IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma
por: Melief, Sara M., et al.
Publicado: (2017)

Immune checkpoint inhibitor (ICI) genes and aging in malignant melanoma patients: a clinicogenomic TCGA study
por: Safi, Mohammed, et al.
Publicado: (2022)

Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort
por: Koskimaa, Hanna-Mari, et al.
Publicado: (2014)

Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative
por: Koskimaa, Hanna-Mari, et al.
Publicado: (2015)

The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study
por: Singh, Satwinder Kaur, et al.
Publicado: (2012)

ICI efficacy information portal: a knowledgebase for responder prediction to immune checkpoint inhibitors
por: Chen, Jiamin, et al.
Publicado: (2023)

Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature
por: Casselman, Pauline, et al.
Publicado: (2023)

Standard radiotherapy but not chemotherapy impairs systemic immunity in non-small cell lung cancer
por: Talebian Yazdi, Mehrdad, et al.
Publicado: (2016)

Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha
por: Verdegaal, Els M. E., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_jb89efi862ujech708543vnmve